非小细胞肺癌患者sCD44v6的检测意义  

作　　者：赵丽红[1] 田建辉[1] 

机构地区：[1]上海中医药大学附属龙华医院,上海200032

出　　处：《实用中西医结合临床》2006年第5期11-12,共2页Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:探讨测定血清可溶性CD44v6含量在非小细胞肺癌(NSCLC)中的临床意义。方法:采用定量酶联免疫反应法(ELISA法)测定75例NSCLC患者及30例正常人血清中可溶性CD44v6(sCD44v6)的含量。结果:NSCLC患者血清sCD44v6的含量明显高于正常人(P<0.001);腺癌、鳞癌、鳞腺混合癌3组之间sCD44v6含量无显著性差异(P>0.05),但与肺癌分期相关,Ⅲ、Ⅳ期患者血清sCD44v6的含量明显高于Ⅰ、Ⅱ期患者(P<0.001,P<0.01)。结论:血清sCD44v6与肺癌的进展和转移密切相关,可作为NSCLC早期诊断的辅助指标,并可作为监测病情进展、转移和预后的指标。Objective： To explore the clinical significance of detecting soluble serum CD44 variant 6 （sCD44v6） in non-small sell lung carcinomas （NSCLC）. Method： Levels of serum sCD44v6 in 75 patients with lung carcinoma and 30 healthy individuals were measured by ELISA. Result： The level of serum sCD44v6 of patients is significantly higher than that in normal person （P 〈0.001）, but no significant difference found between sub-groups divided by pathological classification of adenocarcinoma, squamous carcinoma and Adenosqamous carcinoma （P 〉0.05）. The level of serum sCD44v6 in stage HI and stage IV patients is markedly higher than that in stage I and stage II patients （P 〈0.001,P 〈0.01）, which revealed its close relationship with the stage of disease.Conclusion： The level of serum sCD44v6 correlates with the progression and metastasis of NSCLC. It could be applied as the marker of early diagnosis or metastasis, disease progression and prognosis of NSCLC.

关 键 词：非小细胞肺癌 细胞黏附分子CD44 ELISA法 检测意义 

分 类 号：R734.2[医药卫生—肿瘤]